You are here

  • Home
  • Archive
  • Volume 71, Issue 1
  • First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial

Alerts

Article menu
Inflammatory bowel disease
Original research
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address